US2022290185A1PendingUtilityA1
Nucleic acid-containing lipid particles and related methods
Est. expiryNov 4, 2029(~3.3 yrs left)· nominal 20-yr term from priority
C12N 15/111A61K 9/146C12N 15/88C12N 15/113A61K 9/1272A61K 31/7088A61K 9/145C12N 2310/14C12N 2320/32A61K 47/22
78
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Lipid particles containing a nucleic acid, devices and methods for making the lipid particles, and methods for using the lipid particles.
Claims
exact text as granted — not AI-modified1 . A method for introducing a polynucleic acid into a cell, comprising contacting a cell with a lipid particle, comprising an electron dense core comprising a polynucleic acid and an ionizable lipid, the core coated with one or more polar lipids comprising a PEG-lipid.
2 . The method of claim 1 , wherein the ionizable lipid is an amino lipid.
3 . The method of claim 1 , wherein the ionizable lipid is a dilinoleyl amino lipid.
4 . The method of claim 1 , wherein the ionizable lipid is selected from the group consisting of DODAC, DOTMA, DDAB, DOTAP, DOTAP.Cl, DC-Chol, DOSPA, DOGS, DOPE, DODAP, DODMA, and DMRIE.
5 . The method of claim 1 , wherein the ionizable lipid has the formula:
wherein R 1 and R 2 are either the same or different and independently optionally substituted C 10 -C 24 alkyl, optionally substituted C 10 -C 24 alkenyl, optionally substituted C 10 -C 24 alkynyl, or optionally substituted C 10 -C 24 acyl;
R 3 and R 4 are either the same or different and independently optionally substituted C 1 -C 6 alkyl, optionally substituted C 2 -C 6 alkenyl, or optionally substituted C 2 -C 6 alkynyl or R 3 and R 4 may join to form an optionally substituted heterocyclic ring of 4 to 6 carbon atoms and 1 or 2 heteroatoms chosen from nitrogen and oxygen;
R 5 is either absent or present and when present is hydrogen or C 1 -C 6 alkyl;
m, n, and p are either the same or different and independently either 0 or 1 with the proviso that m, n, and p are not simultaneously 0;
q is 0, 1 , 2, 3, or 4; and
Y and Z are either the same or different and independently O, S, or NH.
6 . The method of claim 1 , wherein the PEG-lipid is selected from the group consisting of PEG-modified phosphatidylethanolamines, PEG-modified phosphatidic acids, PEG-modified ceramides, PEG-modified dialkylamines, PEG-modified diacylglycerols, and PEG-modified dialkylglycerols.
7 . The method of claim 1 , wherein the PEG-lipid is selected from the group consisting of PEG-c-DMA, PEG-c-DOMG, and PEG-s-DMG.
8 . The method of claim 1 , comprising from about 1 to about 5 mole percent PEG-lipid.
9 . The method of claim 1 , comprising about 1 mole percent PEG-lipid.
10 . The method of claim 1 , wherein the polar lipids are selected from the group consisting of neutral lipids and sterols.
11 . The method of claim 1 , wherein the polar lipids comprise a neutral lipid selected from the group consisting of diacylphosphatidylcholines, diacylphosphatidylethanolamines, ceramides, sphingomyelins, dihydrosphingomyelins, cephalins, and cerebrosides.
12 . The method of claim 1 , wherein the polar lipids comprise a neutral lipid selected from DSPC and DOPC.
13 . The method claim 1 , wherein the polar lipids comprise a sterol.
14 . The method of claim 1 , wherein the polynucleic acid is a DNA, an RNA, a locked nucleic acid, a nucleic acid analog, or a plasmid capable of expressing a DNA or an RNA.
15 . The method of claim 1 , wherein the polynucleic acid is ssDNA or dsDNA.
16 . The method of claim 1 , wherein the polynucleic acid is siRNA or microRNA.
17 . The method particle of claim 1 , wherein the polynucleic acid is an oligonucleotide.
18 . The method of claim 1 , wherein the polynucleic acid is an antisense oligonucleotide.
19 . The method of claim 1 , wherein the particle has a diameter from about 30 nm to about 200 nm.
20 . The method of claim 1 , wherein the particle has a diameter of about 80 nm.Join the waitlist — get patent alerts
Track US2022290185A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.